JP7361713B2 - 二環式カルボキサミドおよびその使用方法 - Google Patents

二環式カルボキサミドおよびその使用方法 Download PDF

Info

Publication number
JP7361713B2
JP7361713B2 JP2020555164A JP2020555164A JP7361713B2 JP 7361713 B2 JP7361713 B2 JP 7361713B2 JP 2020555164 A JP2020555164 A JP 2020555164A JP 2020555164 A JP2020555164 A JP 2020555164A JP 7361713 B2 JP7361713 B2 JP 7361713B2
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
cycloalkyl
heterocyclyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521128A (ja
JP2021521128A5 (https=
JPWO2019204523A5 (https=
Inventor
ブラボー，ヤルダ
チー－ユー チェン，オースティン
ディン，ジンユエ
ゴメス，ロバート
ラム，ヘザー
フレッド ナガミゾ，ジョー
マーチェラ オバラ，レナータ
アンドリュー パウエル，デイヴィッド
シェン，タオ
Original Assignee
テンペスト セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テンペスト セラピューティクス，インク． filed Critical テンペスト セラピューティクス，インク．
Publication of JP2021521128A publication Critical patent/JP2021521128A/ja
Publication of JP2021521128A5 publication Critical patent/JP2021521128A5/ja
Publication of JPWO2019204523A5 publication Critical patent/JPWO2019204523A5/ja
Application granted granted Critical
Publication of JP7361713B2 publication Critical patent/JP7361713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020555164A 2018-04-17 2019-04-17 二環式カルボキサミドおよびその使用方法 Active JP7361713B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659068P 2018-04-17 2018-04-17
US62/659,068 2018-04-17
US201862746843P 2018-10-17 2018-10-17
US62/746,843 2018-10-17
PCT/US2019/027992 WO2019204523A1 (en) 2018-04-17 2019-04-17 Bicyclic carboxamides and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2021521128A JP2021521128A (ja) 2021-08-26
JP2021521128A5 JP2021521128A5 (https=) 2022-04-11
JPWO2019204523A5 JPWO2019204523A5 (https=) 2022-04-11
JP7361713B2 true JP7361713B2 (ja) 2023-10-16

Family

ID=66625250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555164A Active JP7361713B2 (ja) 2018-04-17 2019-04-17 二環式カルボキサミドおよびその使用方法

Country Status (14)

Country Link
US (5) US10968201B2 (https=)
EP (1) EP3781550B1 (https=)
JP (1) JP7361713B2 (https=)
KR (1) KR102815312B1 (https=)
CN (1) CN112313208B (https=)
AU (2) AU2019255717B2 (https=)
BR (1) BR112020021042A2 (https=)
CA (1) CA3096894A1 (https=)
DK (1) DK3781550T3 (https=)
ES (1) ES3010282T3 (https=)
IL (1) IL277963B2 (https=)
MX (1) MX2020010879A (https=)
SG (1) SG11202010153WA (https=)
WO (1) WO2019204523A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018255300B2 (en) * 2017-04-18 2021-10-28 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
IL277963B2 (en) 2018-04-17 2024-09-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
CN115448882A (zh) * 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物
CN115448913A (zh) * 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的双环化合物
CN114085167A (zh) * 2021-12-13 2022-02-25 华中药业股份有限公司 一种杂质ts-3a的制备方法
WO2024102968A1 (en) * 2022-11-10 2024-05-16 Tempest Therapeutics, Inc. Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
CN118164967A (zh) * 2022-12-08 2024-06-11 武汉人福创新药物研发中心有限公司 一种ep2、ep4受体拮抗剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
JP2009539886A (ja) 2006-06-12 2009-11-19 メルク フロスト カナダ リミテツド Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体
WO2009139373A1 (ja) 2008-05-14 2009-11-19 アステラス製薬株式会社 アミド化合物
WO2010121382A1 (en) 2009-04-21 2010-10-28 Merck Frosst Canada Ltd. Process for making indole cyclopropyl amide derivatives
WO2017103851A1 (en) 2015-12-17 2017-06-22 Astex Therapeutics Limited Quinoline-3-carboxamides as h-pgds inhibitors
JP2017528477A (ja) 2014-09-13 2017-09-28 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Ｃｒｔｈ２アンタゴニストとしての化合物およびその使用
JP7264060B2 (ja) 2017-04-18 2023-04-25 テンペスト セラピューティクス，インク． 二環式化合物および癌の処置におけるそれらの使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
RU2560818C2 (ru) 2009-04-21 2015-08-20 Эппл Инк Способ и устройство для определения индикатора качества канала в сетях связи, работающих в режиме mu-mimo
EP3375791A1 (en) 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Combination immunotherapy for the treatment of cancer
CN103167875A (zh) * 2010-08-17 2013-06-19 阿勒根公司 用于治疗角膜浑浊的ep2或ep4激动剂
EP2760862B1 (en) * 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9655887B2 (en) 2013-05-23 2017-05-23 Bayer Pharma Aktiengesellschaft Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
TWI730032B (zh) * 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物
HUE057799T2 (hu) 2016-07-07 2022-06-28 Ono Pharmaceutical Co EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombináció
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
IL277963B2 (en) 2018-04-17 2024-09-01 Tempest Therapeutics Inc Bicyclic carboxamides and methods of use thereof
CN115448882A (zh) 2021-06-08 2022-12-09 武汉人福创新药物研发中心有限公司 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物
CN119487006A (zh) 2022-02-24 2025-02-18 广东新契生物医药科技有限公司 作为pge2受体拮抗剂的酰胺化合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539886A (ja) 2006-06-12 2009-11-19 メルク フロスト カナダ リミテツド Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
WO2009139373A1 (ja) 2008-05-14 2009-11-19 アステラス製薬株式会社 アミド化合物
WO2010121382A1 (en) 2009-04-21 2010-10-28 Merck Frosst Canada Ltd. Process for making indole cyclopropyl amide derivatives
JP2017528477A (ja) 2014-09-13 2017-09-28 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Ｃｒｔｈ２アンタゴニストとしての化合物およびその使用
WO2017103851A1 (en) 2015-12-17 2017-06-22 Astex Therapeutics Limited Quinoline-3-carboxamides as h-pgds inhibitors
JP7264060B2 (ja) 2017-04-18 2023-04-25 テンペスト セラピューティクス，インク． 二環式化合物および癌の処置におけるそれらの使用

Also Published As

Publication number Publication date
IL277963B2 (en) 2024-09-01
BR112020021042A2 (pt) 2021-01-19
AU2023201228A1 (en) 2023-04-06
US11472789B2 (en) 2022-10-18
US10968201B2 (en) 2021-04-06
AU2019255717B2 (en) 2022-12-08
AU2019255717A1 (en) 2020-11-26
JP2021521128A (ja) 2021-08-26
SG11202010153WA (en) 2020-11-27
CN112313208B (zh) 2024-04-19
US20190315712A1 (en) 2019-10-17
WO2019204523A1 (en) 2019-10-24
US20250353829A1 (en) 2025-11-20
EP3781550B1 (en) 2024-10-30
ES3010282T3 (en) 2025-04-02
US20230045612A1 (en) 2023-02-09
US12215093B2 (en) 2025-02-04
CA3096894A1 (en) 2019-10-24
US20210024491A1 (en) 2021-01-28
US11795156B2 (en) 2023-10-24
IL277963B1 (en) 2024-05-01
DK3781550T3 (da) 2025-01-27
MX2020010879A (es) 2020-11-09
EP3781550A1 (en) 2021-02-24
KR20210003166A (ko) 2021-01-11
CN112313208A (zh) 2021-02-02
US20240150316A1 (en) 2024-05-09
KR102815312B1 (ko) 2025-05-30
IL277963A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
JP7361713B2 (ja) 二環式カルボキサミドおよびその使用方法
JP7241810B2 (ja) Ｈｐｋ１阻害剤およびそれを用いる方法
KR102588955B1 (ko) 이환식 화합물 및 암의 치료에서의 이의 용도
US11066405B2 (en) Bicyclic compounds and their use in the treatment of cancer
EA044270B1 (ru) Бициклические карбоксамиды и способы их применения
HK40044931A (en) Bicyclic carboxamides and methods of use thereof
HK40044931B (en) Bicyclic carboxamides and methods of use thereof
HK40021223B (en) Bicyclic compounds and their use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230316

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231003

R150 Certificate of patent or registration of utility model

Ref document number: 7361713

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150